Document is current
Any future updates will be listed below
-
Authors
Chowdhury, Saikat
Ito, Ichiaki
Pattalachinti, Vinay K.
Yousef, Abdelrahman M. G.
Yousef, Mahmoud M. G.
El Khoury, Sacha
Hornstein, Nicholas
Seldomridge, Ashlee Nichole
Hong, David
Overman, Micheal J.
Taggart, Melissa W.
Foo, Wai Chin
Helmink, Beth
Fournier, Keith F.
Shen, John Paul
-
Funding
Funding for this research was provided by:
Col. Daniel Connelly Memorial Fund
Andrew Sabin Family Fellowship Award
National Cancer Institute Cancer Center Support Grant (P30 CA016672)
Cancer Prevention and Research Institute of Texas (RR180035)
Appendiceal Cancer Pseudomyxoma Peritonei Research Foundation
Conquer Cancer Career Development Award (2022CDA-7604125121)
- License Information
-
More Information
Article History
Received: 27 February 2026
Accepted: 12 June 2026
First Online: 2 July 2026
Declarations
:
: Patient data were retrospectively collected under the guidance of an IRB-approved study with an informed consent waiver approved by the University of Texas MD Anderson Cancer Center. All animal studies were performed according to protocols approved by the Institutional Animal Care and Use Committee of MD Anderson Cancer Center and conducted in accordance with U.S. Common Rule.
: Not Applicable.
: Dr. John Paul Shen: Grant/Research support/ Collaboration: Natera, Inc; BostonGene; Revolution Medicine; Summit TherapeuticsConsulting / Stock ownership: Engine Biosciences, NaDeNo NanosciencePatent: Siegel D, Schweer J, Abagyan R, Shen JP. SMALL MOLECULE FOR TREATMENT OF CANCER OF THE APPENDIX. Filed July 17, 2023, PCT/US2023/027939Dr. David Hong: Grant/Research support/ Collaboration: 280 Bio, AbbVie, Adaptimmune, Adlai-Nortye, Amgen, Astelles, Astra-Zeneca, Bayer, BeiGene USA, BioBridge, Biomea Fusion, Bristol-Myers Squibb, Deciphera, E.R. Squibb & Sons LLC, Eisai, Eli Lilly, Endeavor, Erasca, Exelixis Inc., F. Hoffmann-LaRoche, Genentech, Immunogenesis, Incyte Inc., Merck, Mirati, NCI-CTEP, Novartis, Pfizer, Quanta Therapeutics, Revolution Medicines, STCube Pharmaceuticals, VM Oncology, and Yiling Pharmaceutical. Travel, accommodations, or expense support: American Association of Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Bayer, BeiGene USA Inc., Genmab, Medscape, Mirati Therapeutics Inc., Pfizer, Society for the Immunotherapy of Cancer (SITC), and Telperian. Consulting, speaker, or advisory role: 280 Bio, Acuta Capital Partners LLC, Alpha Insights, Amgen, Bayer, Boxer Capital, Children’s Oncology Group, COR2ed, Cowen Group Inc, Crossbridge Bio, Ecor1 Capital, Erasca, Gerson Lehrman Group Inc., Group H, Guidepoint, Immunogenesis, Jansen Pharmaceuticals, Kestrel Therapeutics, Medacorp, Medscape, Orbi Capital, Pfizer, Revolution Medicines, T-Knife, Travistock Group, WebMD, and Yiling Pharmaceutical. Ownership interests: Molecular Match (Advisor), OncoResponse (Founder, Advisor), Telperian (Founder, Advisor), and CrossBridge Bio (Advisor).Dr. Michael J. Overman: Consulting/advisory role: Bristol Myers Squibb, Roche/Genentech, Gritstone Bio, MedImmune, Novartis, Array BioPharma, Janssen, Pfizer, 3D Medicines, Merck, Eisai, Simcere; Research funding: Bristol Myers Squibb, Merck, Roche, MedImmune.
